Loading...

Outlook Therapeutics ($OTLK)

Stock Image

OTLK Overview

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications.Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases.Outlook Therapeutics, Inc. has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte.Ltd.; and Zhejiang Huahai Pharmaceutical Company The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018.Outlook Therapeutics, Inc. was founded in 2010 and is headquartered in Cranbury, New Jersey. (From: StockAnalysis.com)

MORE ABOUT Outlook Therapeutics

Stay up to date with the best of Bullish each week.

BULLISH WEEKLY

Stay up to date with the best of Bullish each week.